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Abstract Nail–patella syndrome (NPS) is a pleiotropic
autosomal-dominant disorder due to mutations in the gene
LMX1B. It has traditionally been characterized by a tetrad
of dermatologic and musculoskeletal abnormalities. How-
ever, one of the most serious manifestations of NPS is
kidney disease, which may be present in up to 40% of
affected individuals. Although LMX1B is a developmental
LIM-homeodomain transcription factor, it is expressed in
post-natal life in the glomerular podocyte, suggesting a
regulatory role in that cell. Kidney disease in NPS seems to
occur more often in some families with NPS, but it does not
segregate with any particular mutation type or location.
Two patterns of NPS nephropathy may be distinguished.
Most affected individuals manifest only an accelerated age-
related loss of filtration function in comparison with
unaffected individuals. Development of symptomatic kid-
ney failure is rare in this group, and proteinuria (present in
approximately one-third) does not appear to be progressive.
A small minority (5–10%) of individuals with NPS develop
nephrotic-range proteinuria as early as childhood or young
adulthood and progress to end-stage kidney failure over
variable periods of time. It is proposed that this latter group
reflects the effects of more global podocyte dysfunction,
possibly due to the combination of a mutation in LMX1B
along with an otherwise innocuous polymorphism or
mutation involving any of several genes expressed in
podocytes (e.g. NPHS2, CD2AP), the transription of which
is regulated by LMX1B.










Nail–patella syndrome (NPS, OMIM 161200) is a pleiotro-
pic autosomal-dominant disorder with complete penetrance
but significant variation in its clinical expression [1]. First
described as a hereditary disease by Little in 1897 [2], other
names for NPS include hereditary onycho-osteodysplasia
(HOOD syndrome), Turner–Kieser (or Österreicher–Turner)
syndrome, and Fong disease. The general location of the
responsible gene was deduced relatively early, due to linkage
to the ABO blood group locus [3] and later to the adenylate
kinase gene [4] (long arm of chromosome 9).
The incidence of NPS has been reported to be
approximately 1:50,000, based on estimates by Renwick
many years ago. If the incidence were this high, it would
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suggest that there should be about 6,000 affected individ-
uals in the USA. The number of detected cases appears to
be much lower. Although kindreds of affected individuals
may escape diagnosis for generations [5], leading to the
possibility of very low rates of case ascertainment, it is also
possible that the true incidence of NPS is lower than the
historical value of 1:50,000. The classic tetrad of manifes-
tations of NPS reflect dysplasia of structures derived from
the dorsal mesenchyme. These include absent or hypoplas-
tic finger- and toe nails; absent or hypoplastic patellae;
elbow dysplasia, often involving posterior subluxation of
the radial head; and iliac horns. Although iliac horns are
pathognomonic of NPS, they occur in only approximately
70% of individuals with NPS [1]. Triangular lunules (or
lunulae, the usually crescent-shaped areas at the bases of
the finger- and toenails) are very common in NPS. Other
common findings in NPS include anterior webbing of the
antecubital fossa (pterygium), talipes equinovarus, a lack of
creases over the distal interphalangeal joints, cloverleaf
pigmentation of the iris (Lester’s sign), primary open-angle
glaucoma and ocular hypertension, joint contractures,
lumbar lordosis, underdevelopment of proximal limb
musculature, attention-deficit hyperactivity disorder, senso-
ry neuropathy, sensorineural hearing loss, irritable bowel
syndrome and chronic constipation [1, 6]. Although not
part of the defining tetrad of clinical findings, kidney
disease occurs in greater frequency in individuals with NPS
than in the general population, an association first explicitly
noted by Hawkins and Smith [7] in 1950, although clearly
described by Kieser in 1939 [8]. NPS was recently
reviewed in Pediatric Nephrology [9].
Molecular genetics of NPS
Despite the early discovery of linkage of NPS to the ABO
blood group locus, the specific gene responsible for NPS
was only identified in the late 1990s. Lmx1b (the mouse
ortholog to the human gene, LMX1B) is one of a family of
more than nine LIM-homeodomain genes regulating gene
transcription via its interactions with gene promoter and
enhancer sequences, in conjunction with other transcription
factors. Lmx1b and its ortholog in the chicken (Lmx-1) were
previously known to be involved in dorsoventral limb
patterning. A knockout of Lmx1b in the mouse resulted in a
homozygous phenotype that was highly suggestive of NPS,
albeit manifesting neonatal lethality [10]. The mouse gene
Lmx1b maps to a region syntenic to the known location of
the NPS gene in humans (chromosome 9q34). Based on
this finding, this region was sequenced directly in three
patients with NPS, and three different de novo mutations
were found in LMX1B [11]. NPS was the first human
genetic condition associated with a mutation in a LIM-
homeodomain gene. Another small study described four
novel mutations in four families [12]. In a study of 41
families with NPS, 25 mutations in LMX1B were found by
DNA sequencing and gel analysis in 37 of the families [13].
These included frameshift mutations, single-base deletions,
larger deletions/insertions and single-base substitutions
(leading to nonsense, splice and missense mutations).
Balanced translocations have also been reported [14]. In
families without identified mutations, the relevant DNA
changes are thought to lie in promoter or intronic regions.
Currently, more than 130 distinct mutations in LMX1B have
been described. Most of these are in the LIM domains
(∼80%), with a smaller number in the homeodomain
(∼20%) [9] and a small number in the C-terminal region
of the gene [14]. No mutation is found in 10–15% of
patients investigated. Approximately 12.5% of cases are
sporadic (no demonstrable family history) [1].
The gene is expressed in a number of tissues implicated
in the clinical phenotype in the fetus. In the kidney, it is
expressed in podocytes from the S-shaped body stage on
into post-natal life [10]. Of adult organs, in fact, as shown
by the Northern blot technique, only the kidney expresses
LMX1B [11]. In the nephron, only the glomerulus expresses
the gene [15].
The protein product LMX1B consists of two cysteine-
rich Zn-binding LIM domains in the N-terminal portion, a
60-amino acid homeodomain (HD) and a C-terminal
activation sequence rich in glutamine and serine residues.
The LIM domains underlie protein–protein interactions
with other transcription factors and modifiers [such as the
LIM domain binding protein, Ldb1 (also known as the
cofactor of LIM domains or CLIM2) [16] or basic helix–
loop–helix (bHLH) proteins]; the HD is necessary for
binding of specific promoter and/or enhancer sequences of
DNA (e.g. via the FAR/FLAT sequence element). Missense
mutations in the HD decrease binding to target (FLAT)
sequences [13]. There is significant sequence homology to
LMX1B in other species: 99% amino acid sequence
identity is found among mammals, and even 87% identity
between mammals and teleosts [6]. For this reason HD
segments of human and non-human mammalian orthologs
of LMX1B bind similarly to target DNA sequences in
various test systems, so function of the human gene can, in
principle, be deduced from the behavior of non-human
orthologs.
The gene LMX1B contains eight exons. The transcription
start site is downstream of a cluster of CG-rich sequences
(CpG islands) and is not associated with a consensus TATA
box. This is typical of genes that are transcribed at a low
rate, often under control of the transcription factor Sp1 [14].
With respect to its promoter structure, basal transcription of
LMX1B requires the nucleotide bases from 112 bases
upstream of the transcription start site to 807 bases
downstream from it (i.e. nt −112/+807). There are,
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however, two open reading frames (ORFs) in the presump-
tive 5′-untranslated region (5′-UTR) of the gene, one with
the potential to code for an additional 23 highly conserved
amino acids in-frame with the presumed transcription start
site. Owing to alternative splicing of the last 21 nucleotides
in exon 7, the predicted protein sequence is 372 or 379
amino acids (395 or 402 amino acids including the 23-
amino acid 5′-UTR sequence) [14].
A number of target genes for LMX1B have been
described. The LMX1B product binds to the putative
enhancer sequence of COL4A4 (in the common regulatory
region responsible for coordinate expression of COL4A4
and COL4A3 [17], two of the three genes required for
production of mature type IV collagen in the glomerular
basement membrane, GBM). The mouse knockout
Lmx1b−/− has strongly decreased expression of α(3) and
α(4) chains of type IV collagen, while the heterozygous
Lmx1b+/− has moderately decreased expression of the
relevant mRNA species [18]. On the other hand, expres-
sion of all three chains (α3, α4, α5) of type IV collagen is
shown to be normal by immunohistochemical analysis in
the glomeruli from biopsies of humans with NPS [19].
Expression of the podocyte-related genes CD2AP and
NPHS2 is also reduced in the Lmx1b−/− mouse [17, 20],
although, again, not in affected humans [19]. Each of these
genes has FLAT elements flanking the first exons. However,
although Lmx1b binds a FLAT element in the NPHS2
promoter, there have been conflicting reports regarding its
ability to activate a reporter gene on that promoter [17, 20],
possibly due to the lack of an essential transcription cofactor
in some, but not all, of the expression systems used.
LMX1B is thought to interact with other gene regulatory
proteins: negatively with Ldb1 and positively with the
bHLH protein, E47 [21]. The bHLH transcription factor
Pod1 is expressed in parallel fashion with Lmx1b in the
kidney, but Pod1 and Lmx1b have not been shown to
interact as transcriptional cofactors [22]. With its two LIM
domains, LMX1B is likely to have multiple regulatory
protein ‘partners’. The renal development transcription
factor, PAX2, for example, has been shown by Marini and
colleagues [23] to interact with LMX1B only in the
presence of the latter’s HD (inasmuch as deletion of the
HD abrogated the interaction, whereas deletion of the LIM
domains did not). This suggests that a structural change in
LMX1B upon DNA binding may facilitate its interaction
with other proteins.
In any autosomal dominant condition, different possibil-
ities exist for the mechanism by which mutation in a single
allele alters aggregate gene function. In the case of LMX1B,
haplo-insufficiency or a dominant negative effect have been
the mechanisms most often discussed. There is also the
theoretical possibility of a gain-of-function mutation (e.g.
as in hypoxia-inducible factor-α, HIFα). In the dominant
negative mechanism, an abnormal gene product interferes
with the normal actions of the wildtype (WT) product in the
same cell, either by forming a non-functional dimer (if, for
example, the functional gene product is a homodimer) or by
strongly and competitively binding to, but not activating,
the target DNA sequence. This mechanism often leads to a
more severe phenotype than a simple null mutation. In
various in vitro systems, co-expression of both mutant and
WT Lmx1b did not interfere with activation of a reporter
construct by the WT product [21, 24], suggesting haplo-
insufficiency as the fundamental mechanism. It is, as yet,
unclear why NPS shows autosomal dominant genetics in
humans and an autosomal recessive pattern in the mouse. A
recent study of a podocyte-specific Lmx1b knockout (using
a Cre-Lox system based on the NPHS2 promoter) showed
later development of proteinuria and greater expression of
type IV collagen chains and podocin, although the animals
still died of kidney failure within 14 days [15]. Thus, even
this model still represents a more severe kidney phenotype
than in the human disease.
The presence of significant phenotypic variation in a
presumably monogenic disorder makes NPS an attractive
subject for both clinical and basic investigations. Over
50 years ago, Renwick suggested that the NPS allele of the
unaffected parent was responsible for variations in disease
severity (as manifested in an orthopedic ‘score’ of nail or
patellar signs). Recently, Dunston and colleagues [25]
examined this modifier allele effect in 103 individuals,
using a similar quantitative nail scoring system and single
nucleotide polymorphism (SNP) haplotype profiling to
establish allelic inheritance. Contrary to the findings and
interpretation of Renwick [26], those authors found
evidence that the NPS allele of the affected parent (but
not the specific mutation) influenced the severity of nail
dysplasia, suggesting the influence of a cis-acting element
near the mutant gene. As yet, there has been no study
associating SNP haplotypes to either the presence of
nephropathy or quantitative proteinuria, analogous to
Dunston’s work on nail dysplasia.
Clinical manifestations
Because of the rarity of the disorder, most publications
concerning kidney involvement in NPS have either been
case reports or small series. Involvement of the kidney as a
feature of NPS was first reported in 1950 [7]. Hematuria
and proteinuria have often been noted, as have numerous
anecdotal reports of progression to kidney failure, even in
childhood [27]. In fact, the reported cases of kidney failure
do not seem to conform to the typical progressive pattern of
other genetic diseases, such as Alport syndrome. Other
renal abnormalities (urologic malformations, nephrolithia-
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sis) have been reported anecdotally [27–29] but have not
been investigated systematically.
Only a limited number of larger series (involving 36 to
236 individuals) addressing kidney involvement in NPS
have been reported [1, 27, 28, 30–32], and there have been
no longitudinal studies on kidney involvement in NPS. The
larger studies represent patients from a single center [28],
from a systematic cross-sectional multi-site survey [1] or
collected from multiple centers and published reports [27,
30–32]. Thus, ascertainment of subjects has always been
potentially biased towards more severe referral cases; the
closest to an unbiased ascertainment is probably in the reports
of Sweeney and colleagues [1] and Bongers and colleagues
[31]. In the five largest series [1, 27, 30–32], screening for
kidney involvement involved the questioning of subjects and
simple urinalysis, spot urine protein(albumin)/creatinine
ratios and/or estimated glomerular filtration rate (GFR), or
it could not be deduced from the description of the methods
in the published reports. Among the larger series, hematuria
was only specifically reported in three studies [1, 27, 31]. In
these the incidence was approximately 10–20%. The
presence of elbow pterygia has been reported to be
associated with the presence of nephropathy in NPS [33],
but this was not substantiated in a large study [1].
In the study of 36 affected individuals by Bennett and
colleagues [28], in addition to a dipstick urinalysis, 4 h
creatinine clearance was done as a part of the screening.
Follow-up determinations of urinary protein excretion were
performed only in those individuals having a positive result
for the urine dipstick test for protein. Nineteen of the 36
NPS subjects underwent more extensive investigations,
including that of 24 h creatinine clearance and quantitative
proteinuria determinations. Of these, only one subject (a
21-year-old woman with proliferative glomerulonephritis)
had a creatinine clearance less than 75 ml/min per 1.73 m2
body surface area. Two subjects (both children) had
nephrotic syndrome, and three adults had moderate pro-
teinuria (130–350 mg/day). The incidence of hypertension
was not mentioned in that study.
In the 1988 study of Looij and colleagues [30] of
approximately 240 affected individuals, the risk of ne-
phropathy in 118–131 subjects having a parental history of
NPS nephropathy (47–59%) was about the same as that of
the group as whole (48%). Similarly, the risk of kidney
failure was the same in individuals with (15%) and without
(14%) a parental history of NPS and kidney failure.
Meyrier and colleagues [27] reported that, of 123 patients
with NPS with adequate information, 62% had some sign
of kidney involvement (proteinuria, hematuria, hyperten-
sion or kidney failure); of these, approximately 15% had
developed kidney failure. They also reported on a pair of
identical twins with NPS, one of whom progressed rapidly
to kidney failure, while the other remained “only proteinu-
ric”. Sweeney and colleagues [1] studied 123 British NPS
patients (ages 4 months to 80 years) from 43 families. The
patients were ascertained via clinical genetics departments,
patient contact groups and nephrologists. The authors found
an overall incidence of kidney involvement (as determined
by urine dipstick analysis and clinical history) of 37.5%.
With the exclusion of those subjects with clinical findings
only during pregnancy, the rate was 25%. Only 3% had
developed kidney failure, whereas the incidence of pre-
eclampsia in women with NPS was 29%, approximately
ten-times the incidence in the general population [1]. Other,
isolated, cases of pre-eclampsia in NPS have been reported
[34]. Knoers and colleagues [32] investigated NPS geno-
types in eight affected Dutch families (66 individuals;
sporadic in three families). The subjects had some overlap
with those reported earlier by Looij and colleagues in 1988.
The authors expressed doubt that the high incidence of
kidney disease in the largest of the families (present in 13
of 30 individuals, reported previously in [30]) could be
related to the familial LMX1B genotype, inasmuch as the
family contained affected individuals with no evidence of
kidney disease, individuals with mild proteinuria alone and
individuals whose condition had progressed to kidney
failure. Of interest, that family’s specific genotype (the
splice-site mutation 672+1 G→A) was not associated with
occurrence of nephropathy in an unrelated kindred [13].
Finally, in a recent study of 106 individuals from 32
families [31], some of whom had been reported on in
previously published studies from the same center [30, 32],
urinary studies were performed on 81 subjects ranging from
6 months to 82 years of age. Microalbuminuria was present
in 27.5% of morning urine specimens, while macroalbumi-
nuria (defined as >300 μg albumin/10 mM creatinine)
occurred in 3.6%. Estimated GFR was <60 ml/min per
1.73 m2 in 5.3% and between 60 ml/min per 1.73 m2 and
90 ml/min per 1.73 m2 in 34.2%. The authors estimated
GFR using the formula of Cockroft and Gault. It must be
kept in mind that a low relative muscle mass, typical in
individuals with NPS [1], may lead to lower creatinine
production rates and spuriously elevated renal function as
estimated by the Cockcroft–Gault and other equations.
Unlike the previous interpretation of their data, in this
report the authors proposed that nephropathy was more
common in individuals with mutations in the HD region.
Acknowledging the overriding influence of the single large
family mentioned above, they stated that a significant effect
of genotype on nephropathy risk was still present when this
family was removed (53% of the variation in proteinuria
was attributable to family and 30% to LMX1B genotype).
The incidence of hypertension was not mentioned in their
report. They did report that proteinuric subjects were older
than non-proteinuric subjects (48 years vs 36 years, P=
0.03) and that the GFR in proteinuric subjects was less than
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in non-proteinuric subjects (78 ml/min per 1.73 m2 vs
100 ml/min per 1.73 m2).
It seems likely that many of the earlier studies of kidney
involvement in NPS may not have identified all individuals
with low-grade proteinuria. Results of standard dipstick
tests are only reliably positive for proteinuria in urine
specimens having albumin/creatinine ratios over approxi-
mately 300 μg/mg, whereas urinary albumin excretion in
healthy individuals corresponds to a ratio less than 30 μg/
mg. Thus, dipstick screening will not detect some individ-
uals with low-grade albuminuria. The importance of the
detection of proteinuria in the occult, microalbuminuric
stage (spot urinary albumin/creatinine ratios from 30 μg/mg
to 299 μg/mg) has been emphasized principally in patients
with type 1 diabetes, as diabetic individuals with persistent
microalbuminuria have a substantially increased risk of
developing overt nephropathy over time [35, 36]. The same
has not been demonstrated in NPS.
The lack of longitudinal studies of kidney involvement
in NPS makes it difficult, if not impossible, to determine
precisely which clinical features characterize progression to
end-stage kidney failure. For example, it is, as yet,
unknown if such patients always manifest nephrotic-range
proteinuria prior to progression to kidney failure.
Pathology of NPS in the kidney
In the animal model of NPS (the Lmx1b−/− mouse) the
podocytes and glomeruli seem to have arrested develop-
ment, with capillary ingress but not arborization. Podocytes
lack normal foot processes and slit diaphragms (adherens
junctions may be present instead, between podocytes)
[17, 20]. The glomerular tuft is small, the GBM is split, the
glomerular endothelial cells have decreased fenestrae, and
fibrin-like material may be deposited in Bowman’s space
[20]. In addition to these findings, lifting of glomerular
capillary endothelial cells off the GBM has been described
in mice with podocyte-specific homozygous deletion of
Lmx1b [15], which also present with later-onset kidney
injury and death. Staining for some podocyte-related
proteins [CD2-associated protein (CD2AP), podocin], but
not others (nephrin, synaptopodin), is significantly de-
creased [20, 37].
The first description of ultrastructural abnormalities in
the NPS kidney was published in 1970 [38]. On light
microscopy, the glomeruli of individuals with NPS are not,
in general, remarkable, with the exception of variable
amounts of glomerular sclerosis. On electron microscopy,
patients with NPS show characteristic irregular thickening
of the glomerular basement membrane, including deposits
of bundles of striated type III collagen fibers in the lamina
densa [19] and patchy lucent (“moth-eaten”) areas (Fig. 1).
Fibrillar collagen bundles are also occasionally seen in the
mesangial matrix. Staining with phosphotungstic acid may
improve visibility of these collagen bundles over routine
uranyl acetate/lead citrate staining. Foot processes are
normal or focally effaced [19]. There are few reports
commenting on the presence or abnormality of slit
diaphragms in NPS patients. In the study by Heidet and
colleagues [19], slit diaphragms are simply reported as
being “preserved”. Immunofluorescence microscopy gives
negative findings or shows non-specific staining for IgM,
C3 and/or C1q, often in sclerotic portions of the tuft. Fibrin
deposition along the GBM may be a rare finding in humans
[28]. Unlike the homozygous mouse model, in patients with
NPS the glomeruli stain normally for the α3 and α4 chains
of type IV collagen, podocin, synaptopodin, glomerular
epithelial protein 1 (GLEPP1), CD2AP, α3 integrin and
nephrin.
NPS in the kidney must be distinguished from collagen
type III glomerulopathy [39]. The latter autosomal recessive
hereditary nephropathy has distinct systemic manifestations
and demonstrates widespread deposition of type III colla-
gen within the mesangial matrix and along the subendothe-
lial aspect of a normal lamina densa of the GBM.
Numerous reports exist of NPS patients having biopsy
diagnoses of other renal diseases (Goodpasture syndrome,
IgA nephropathy, membranous nephropathy, hemolytic
uremic syndrome), although the significance of these
anecdotal associations is uncertain. Typical ultrastructural
findings of NPS may be found in individuals with no
Fig. 1 Electron micrograph from patient with NPS and nephrotic-
range proteinuria. Notice the extensive effacement of podocyte foot
processes and the irregular thickening of the glomerular basement
membrane with scattered deposits of collagen fibrils. Stained with lead
citrate and uranyl acetate
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clinical evidence of kidney involvement, and the severity of
specific pathologic findings seems largely unrelated to the
clinical severity or prognosis [28]. On the other hand, a
patient with long-standing hematuria and proteinuria and
typical findings of NPS on renal biopsy by report did not
have any nail or skeletal findings of NPS [40]. No mutation
analysis was provided in this report. There have been no
reported series of repeat biopsies of patients with NPS to
answer such questions as to whether the typical GBM
abnormalities are progressive.
Diagnosis of NPS
A diagnosis of NPS is suggested by the usual tetrad of
musculoskeletal features: absent/dysplastic nails, absent/
hypoplastic patellae, elbow dysplasia or radial subluxation,
iliac horns. Although diagnosis can be made at birth, it is
often missed, presumably due to the rarity of the condition
and its sometimes subtle clinical forms. Owing to the
phenotypic variability of NPS, it is advisable that a clinical
geneticist be consulted to confirm a suspected diagnosis.
Pre-natal (first trimester) diagnosis is possible using
chorionic villus sampling, either with marker haplotyping
or kindred-specific mutation analysis [41]. Commercial
gene sequence analysis is also available from multiple
laboratories in the USA and abroad (see www.genetests.org
for contact information).
Biopsy to investigate the possibility of the presence of
another kidney disease in patients with NPS could be
justified if signs and symptoms of another form of
nephropathy are also present (lupus, diabetic nephropathy).
As there is no clear relationship between the renal
pathology of NPS and its clinical behavior, kidney biopsy
in cases of NPS with classical features is to be discouraged.
Care for individuals with NPS
Owing to the rarity of NPS, many affected individuals find
it difficult to obtain comprehensive care from their primary
care provider, who is likely to be completely unfamiliar
with the multiple clinical manifestations of NPS when the
patient first walks into the office. It is often a subspecialist
(orthopedist, nephrologist, geneticist) who eventually coor-
dinates care. The treating physician should carefully
balance investigating every possible clinical component of
the disease state and blindly ascribing any (possibly
unrelated) clinical finding to NPS.
It has been suggested that screening for nephropathy be
done annually, starting at birth. In the absence of other
signs of nephrotic syndrome, as well as any evidence that
early intervention affects clinical outcome, it seems likely
that deferring annual screening until a child can reliably
give a specimen by spontaneous voiding (“clean catch”)
may be an acceptable strategy. Although spot urine protein/
creatinine or albumin/creatinine ratios are more sensitive
than routine urinary dipstick analysis, there is, as yet, no
evidence that intervention in the microalbuminuric phase
will alter outcome. Other routine screening is ophthalmol-
ogy examination for detection of glaucoma.
Treatment of the nephropathy of NPS
Progressive kidney disease affects a small minority of
patients with NPS: estimates range from 3% [1] to 15%
[27, 30]. Significant questions remain concerning the
prognosis of individuals detected with abnormal albumin-
uria and a normal GFR. Nephrotic-range proteinuria has
often been associated with loss of kidney function over
variable periods of time. Patients with proteinuria and long-
term stability of kidney function have also been mentioned
in the literature (although usually without much clinical
data). As it is a genetic disease, not surprisingly, there are
no specific treatments for kidney involvement in NPS. A
strongly renoprotective effect of angiotensin-converting
enzyme (ACE) inhibition on disease progression has been
demonstrated in a variety of non-diabetic, proteinuric,
glomerular diseases [42], raising the possibility that
treatment with ACE inhibitors might provide equivalent
protection to proteinuric patients with NPS (vide infra). In
the author’s personal experience, treatment with low-dose
ACE inhibitors in an 8-year-old child with NPS reduced the
urine protein/creatinine ratio from 2.2–2.8 mg/mg to 0.4–
0.8 mg/mg. It seems likely that the development of national
or multinational disease registries for NPS will be necessary
in order to follow effectively the relatively small number of
NPS patients with known kidney involvement and allow
the acquisition of the longitudinal data needed to evaluate
both potential prognostic markers (e.g. proteinuria) and
possible therapeutic interventions such as ACE inhibition.
A novel, and unexpected, therapy has been described in
recent years for another genetic disease characterized by
abnormalities of the GBM, Alport syndrome. Cyclosporin has
been described in some, but not all, reports as decreasing
proteinuria and stabilizing kidney function [43, 44]. Although
no studies have addressed its use in NPS with high-grade
proteinuria, a trial of cyclosporin may be a reasonable option
for individuals whose condition is resistant to the anti-
proteinuric action of ACE inhibitors or in whom unaccept-
able side effects (hypotension, angioedema) develop.
There are numerous anecdotes of patients with NPS who
have undergone successful transplantation after developing
terminal kidney failure. A normal distribution of type IV
collagen and various podocyte proteins in the human
disorder may explain why there is apparently no develop-
ment of (antibody-mediated) neo-antigen disease in trans-
plant recipients. Generally, patients with NPS and kidney
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failure should be considered excellent candidates for kidney
transplantation. NPS should, of course, be excluded from
potential related kidney donors.
The Pittsburgh study
As stated above, there have been no published longitudinal
studies of kidney function in patients with NPS. In 2002,
my colleagues (Adele Towers, Ketki Desai and Iain
McIntosh) and I undertook a study of various aspects of
the NPS phenotype, including kidney function. By exam-
ining the effects of age on kidney function in a large cross-
sectional study, we simulated longitudinal changes in NPS,
using each individual as a surrogate for a temporal cross-
section of a “global (corporate) individual”. The partic-
ipants at the 2002 national conference of the patient support
organization Nail–Patella Syndrome Worldwide (NPSW,
www.nailpatella.org) were invited to participate in a study
approved by the Institutional Review Board of the
University of Pittsburgh School of Medicine. Twenty-five
children (ages 2–17 years) and 32 adults (ages 21–69 years)
with a diagnosis of NPS confirmed by a clinical geneticist
were enrolled, representing 29 kindreds. Participants un-
derwent measurement of blood pressure, serum creatinine
and urine albumin/creatinine ratio (not all measurements
were obtained in all individuals). A study of bone health in
this group has been reported [45]. GFR in the children was
estimated from the Schwartz formula [46], and, in the
adults, creatinine clearance was estimated by the Cock-
croft–Gault formula, corrected for body surface area (BSA),
as described before [31]. Normal values for adults were
derived from data from 138 healthy, age-matched unaffect-
ed individuals (21–69 years) previously studied at Stanford
University (unpublished observations). LMX1B mutation
analysis was performed as previously described [13].
Mutations were characterized as null, missense LIM or
missense homeodomain. None of the subjects had devel-
oped end-stage kidney disease. One child and two adults
were taking ACE inhibitors.
Hypertension was rare (none of 19 children, two of 28
adults, had mild stage 1 hypertension). Six of 17 children
and eight of 30 adults had proteinuria. There was no
relationship between age and albumin/creatinine ratio in the
adults (P=0.997). All children had a normal estimated GFR
(n=10; 156±24 standard deviation (SD) ml/min per
1.73 m2 BSA). In 26 adults, the estimated creatinine
clearance, corrected for BSA, was 93±24 ml/min per
1.73 m2. The control adults had a higher average creatinine
clearance (113±21 ml/min per 1.73 m2, P<0.001). The rate
of decline of the creatinine clearance with age in the adults
with NPS was 1.15±0.33 standard error (SE) ml/min per
1.73 m2 per year (P=0.002) compared to 0.50±0.13 ml/min
per 1.73 m2 per year (P=0.0002) in controls. The control
value was quite similar to the rate of decline of measured
24 h creatinine clearance with age (0.50–0.62 ml/min per
1.73 m2 per year) previously described in healthy men
[47, 48].
To examine the effects of normal aging on kidney
function in NPS, we looked at the relationship between
creatinine clearance and age in affected individuals who did
not have overtly decreased kidney function. Although two
subjects had decreased age-specific creatinine clearances
when compared to the reference unaffected population (a
35-year-old woman with a clearance of 48 ml/min per
1.73 m2 and a 53-year-old man with a clearance of 50 ml/
min per 1.73 m2), we removed from the analysis only that
subject whose creatinine clearance fell outside the 95th
percentile range of the regression of creatinine clearance on
age among the individuals with NPS; that is, we let the
regression relationship define the normal rate of change of
creatinine clearance with age in NPS. The decline in
creatinine clearance in the remaining 25 subjects with
NPS, 1.29±0.28 SE ml/min per 1.73 m2 per year, was
significantly greater than that in the controls (P=0.018)
(Fig. 2).
Kidney involvement seemed to be differently distributed
among the various NPS mutations. Twenty-five different
mutations were included in our sample, representing
approximately 18% of those mutations that have been
previously described [14]. Of those mutations present in
two or more individuals, kidney involvement (defined as
decreased creatinine clearance, proteinuria or hyperten-
sion) seemed to occur with increased frequency in c.819+
Fig. 2 Creatinine clearance age-matched controls (small circles, solid
line, n=138) and 25 adult subjects with NPS (large circles, dashed
line). The slopes of the regressions differ significantly (0.50±0.13 vs
1.29±0.28 SE ml/min per 1.73 m2 per year; P=0.018)
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1G →A (two of two), p.C146Y (two of three) and p.
L252P (three of three). In this terminology, c.819+1G→A
means the substitution of an adenosine for a guanosine at
the first nucleotide of the intron that follows the cDNA
(c.) position 819; p.C146Y means a change in the 146th
amino acid of the protein (p.) from cysteine to tyrosine
(Y) [49]. A decreased frequency of kidney involvement
seemed to be a feature of mutations p.Q60X (one of nine),
p.R221X (none of four), and p.R231X (none of six).
Statistical examination of the 11 mutations represented by
more than one individual suggested non-random clustering
of affected individuals among the different mutations (χ2=
24; P=0.008). The three most common mutations associ-
ated with kidney involvement, however, were each of a
different type: c.819+1G →A is a null mutation; p.C146Y
is a missense mutation in the LIM-B domain; p.L252P is a
missense mutation in the homeodomain. Thus, as with the
study by Knoers and colleagues [32], although there was
evidence for familial aggregation of nephropathy, we found
no convincing evidence for a specific “nephropathy locus”
in LMX1B.
NPS nephropathy: a possible mechanism
As NPS is a genetic disease, it is clear that its clinical
manifestations are a result of mutations in or around the
gene LMX1B. Since kidney function exists at the level of
the organ (or at least its major structural components, the
glomerulus and the tubule), the renal manifestations of NPS
belong to the realm of physiology and not of molecular
biology. In short, we ultimately need to address how we get
from gene to GFR. Nephropathy in NPS (both in terms of
proteinuria and loss of GFR) seems to be characterized by
rather extreme phenotypic variability. I propose that kidney
involvement in NPS can be understood in terms of two
distinct mechanisms. First, the vast majority (90–95%) of
individuals with NPS have a slowly progressive loss of
filtration function with age, at approximately twice the rate
associated with normal aging in unaffected individuals.
This is likely due to progressive thickening and disorgani-
zation of the GBM, lowering the hydraulic permeability of
the glomerular capillary wall [50]. No pathology studies
address whether the thickening of the GBM in NPS is
progressive. There is low-grade, non-progressive, protein-
uria in a minority of these individuals, suggesting that
global podocyte dysfunction is not present. A small
proportion (5–10%) of patients manifest greater amounts
of proteinuria and tend to have a progressive, albeit
variable, course to kidney failure. It seems possible that
these individuals have, in addition to the single heterozy-
gous LMX1B mutation, another heterozygous mutation or
polymorphism in the exons, promoter or enhancer elements
of a gene pivotal to podocyte function (e.g. NPHS1,
NPHS2, CD2AP, ACTN4), the expression of which is
regulated by LMX1B. The latter mutation/polymorphism
alone would not lead to a renal phenotype, but, in
conjunction with haplo-insufficiency in LMX1B, it leads
to varying degrees of podocyte dysfunction. The variability
of the rate of progression may result from the particular
combination of podocyte gene changes. This could certain-
ly explain the increased, but not universal, occurrence of
more severe kidney involvement within some families (but
not with specific LMX1B mutation types), as these other
mutations/polymorphisms would be expected to segregate
independently from LMX1B (e.g. NPHS2 is on chromo-
some 1). It is intriguing in this regard to consider the report
[51] that a neonate in Finland with NPS had transient
nephrotic syndrome at birth. It seems possible that this was
the effect of heterozygous mutations in LMX1B and
NPHS1, although the transient nature of the nephrosis is
difficult to explain under this model.
If the age-related loss of filtration function in most adults
with NPS is not due to global podocyte dysfunction (as
suggested by the lack development of progressive protein-
uria) but rather to thickening of the GBM, it is open to
question as to how effective ACE inhibition would be in the
stabilization of glomerular filtration function in these
individuals with NPS. On the other hand, anecdotal
experience suggests that these individuals are not at high
risk for developing end-stage kidney failure over the course
of a normal lifetime. Thus, it is to the relatively small
number of NPS patients with either nephrotic-range
proteinuria or evidence of significant loss of GFR that we
should direct our efforts to find an effective treatment.
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Questions
(Answers appear after the reference list)
1. Which of the following is not one of the classic tetrad
of diagnostic features of NPS:
2352 Pediatr Nephrol (2009) 24:2345–2354
A. dysplastic finger or toe nails
B. elbow dysplasia
C. low-set ears
D. hypoplastic or absent patellae
2. The gene responsible for NPS—LMX1B—is
A. expressed only after birth
B. on the X chromosome
C. a LIM-homeodomain transcription factor
D. quite different in sequence from its non-human
mammalian orthologs
3. Kidney failure in NPS is
A. associated with sensorineural hearing loss
B. rare under the age of 40 years
C. relatively uncommon (5–10% of individuals)
D. associated with more severe changes of the GBM
on biopsy
4. Some sign of kidney involvement (hematuria, protein-
uria, increased creatinine) in NPS is found in
A. <10% of individuals
B. 10–20% of individuals
C. 30–40% of individuals
D. 100% of individuals
5. The pathology of NPS in the kidney is characterized by
A. diffuse IgG deposits in the mesangium
B. fibrillar collagen in the lamina densa of the GBM
C. its close prognostic connection to functional
outcome
D. being non-specific for this disorder
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